Long-acting risperidone and oral antipsychotics in unstable schizophrenia. - Wikidata - wikimedia - TriplyDB

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

http://www.wikidata.org/entity/Q48900125

about

Risperidone (depot) for schizophrenia Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.The impact of missing data on the results of a schizophrenia study.Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data.Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization.Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment.Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates The reduction of volume and fiber bundle connections in the hippocampus of EGR3 transgenic schizophrenia rats.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model.Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders Increased use of antipsychotic long-acting injections with community treatment orders.The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria.Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.Progress in compliance research and intervention: a commentary.Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Schizophrenia guidelines across the world: a selective review and comparison.Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals.

P2860

Q24185901-FD764B41-0EDA-49ED-8647-E8E3B8B13342 Q24597701-7961CA95-2798-49ED-B9C1-8CAE9CBF8E3F Q26752965-0177E29D-1227-4BEB-9312-AA730712128A Q26863435-0F64A350-AD14-4F2F-8D79-7173F5500B6A Q27320151-4CA5799E-2166-487E-A080-372DB6ECA2FF Q28084069-70F8911F-DB61-45BB-BF23-8EAEAD49F21E Q28085407-15DCB6D0-BEA1-49E0-B5A0-90715552E1E4 Q30542486-7078E90E-9EAD-46E0-A79D-6A072A88497A Q30862474-540723DE-5839-4955-A357-BDCB847A2C64 Q30863128-970458E7-93C8-403D-B555-65970A2EFF60 Q33718170-5A357C92-A296-436E-993E-9D7ADB091664 Q33740800-85C52063-0E7F-4D7C-87AA-A085C0B49DF4 Q33802918-2E8BD1A4-6995-4322-92BE-29212C4A19D6 Q33914295-A08E5A99-C89C-4DCE-BD46-8A06FC3FD005 Q34293899-FBD47AA7-A186-4D3B-9918-D938A4305E31 Q34315836-CE92A79B-A044-497A-81F1-02291ADD9845 Q34357174-5D746B15-6AAC-4D7B-A3AC-9886596BE8D6 Q34375554-C47F718E-A91E-4C85-8D7B-42BF0C7641C0 Q34693244-3CDCF7CD-97E5-4892-9F4A-9BA29FF1DE01 Q34775426-7F8EB96D-875C-4D42-930F-963E551D99E2 Q35249595-1CC78B9E-EBB7-4CC8-BEC6-DD33555DF8DC Q35688404-67B78001-A62E-4E40-8A0E-E38A649B5B08 Q35827695-143A5C4A-C5EA-4F1E-8D0A-F77C5BD59461 Q35971060-6586DC49-70DB-4B3F-BDB3-39AF27E833DE Q36059843-137D82B1-358E-45E6-BD23-FD89D8D89D64 Q36144552-3BBF3C8E-FACC-40A1-8294-65729F8E7E70 Q36183650-A4867AF9-343E-417B-AAF1-EA0C1CB6B5F4 Q36211694-DD6E262E-4FE2-43EF-B145-1342B1834AEA Q36445106-E4B08728-02E3-454C-BFEB-CCA2044DD435 Q36672952-1A1CCEC0-DC92-46C2-99C9-C56C3A2D292C Q36884944-E4891D63-38A0-488D-A1D5-215B62E69EF6 Q36927085-98D03257-9522-4F03-881E-C410A2D30746 Q37078942-2D8719FD-781F-4ADB-8A4B-FF6D6B70146D Q37079053-749D76CA-0302-49DB-86E4-F94F2250AD0A Q37236148-86F1C8B5-61C8-464D-A2E5-FB6BD00A505E Q37236153-C8703D53-928D-45D3-9DD4-932EEA148B78 Q37341552-34969404-802E-496D-A053-426E12D45014 Q37451403-415A03A9-A1F9-4E52-B8C9-507514D66746 Q37949405-0A58DE1B-6434-4BBF-BA1F-6D3DAE3CFAE7 Q38010780-DF22DFA1-B4A5-43A2-A9BB-BD6571BE1ED9

P2860

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

http://www.wikidata.org/entity/Q48900125

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@en

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@nl

type

label

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@en

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@nl

prefLabel

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@en

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@nl

P1433

Q48900125-0CC615FC-361F-4A79-BF2D-85F1B14F6A00

P1476

Q48900125-37511356-BFE8-4E30-A539-3899D26BE91C

P2093

Q48900125-1450542A-F665-4991-A207-08B8FE83FBD6

Q48900125-3E4504BE-6445-4EA9-AACA-DB8A13E2D58C

Q48900125-6E5B8EBB-19AA-4D2A-9E54-7BC4DA2D7E51

Q48900125-8B267FD0-D77D-4E67-B096-0D7BA2D51A2B

Q48900125-C1F671D2-D36E-4B1C-87B9-CA9841364FD3

Q48900125-DBCF9499-F5C1-4514-A39B-DAA16D961D87

Q48900125-DE0DED8E-EA8D-46AE-8793-6763E6FDA662

Q48900125-F50ED0DB-3DD0-4E98-A5A2-3D6FB0E77905

Q48900125-FAAE53CB-27E4-4FA4-BC3F-597E08A13732

P304

Q48900125-3AFD5440-6D21-4B1A-8AC9-C12D9AA6590E

P31

Q48900125-AEF6FA03-B03F-4ABF-AD8C-7DE1F1D804E4

P356

Q48900125-325C817A-255E-4DC4-9C06-345A2C210F4E

P407

Q48900125-6D7FA82A-DD4E-46F9-B5E8-18A51F89382D

P433

Q48900125-BF31629D-DF63-406D-86EF-D760217605B6

P478

Q48900125-694F7E00-4F95-4F0B-8EED-C56ADB421105

P50

Q48900125-14040A85-CE88-4EAD-8A48-D7E09F6B9504

P577

Q48900125-50176620-C245-4463-9B44-61508C1200E6

P698

Q48900125-AF610A5F-9F0F-4DE8-8003-017BC712C3BE

P921

Q48900125-9E02DFEB-D933-4873-8891-6194493FE963

P356

P1433

The New England Journal of Medicine

P1476

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

@en

P2093

CSP555 Research Group

http://www.w3.org/2001/XMLSchema#string

Danielle Valley

http://www.w3.org/2001/XMLSchema#string

John H Krystal

http://www.w3.org/2001/XMLSchema#string

Julia E Vertrees

http://www.w3.org/2001/XMLSchema#string

Louis Fiore

http://www.w3.org/2001/XMLSchema#string

Matthew H Liang

http://www.w3.org/2001/XMLSchema#string

Paul G Barnett

http://www.w3.org/2001/XMLSchema#string

Robert Lew

http://www.w3.org/2001/XMLSchema#string

Soe Soe Thwin

http://www.w3.org/2001/XMLSchema#string

P304

842-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1005987

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Robert A. Rosenheck

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21366475

http://www.w3.org/2001/XMLSchema#string

P921